Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (535)	2/8/2000 1:38:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 675

Thanks to cnsi for press release hard copies, shareholders should be getting them in the mail about now. Reading these over once again, here were some highlights. From the Nov 29th, 1999 PR: GGF2, 14 patents and 54 pending, gee, I think they have that growth factor covered. From the Dec 14th, 1999 PR: More patents, "The claims covered by these patents provide additional support for cnsi's collaboration with Allergan in the discovery of novel vision-sparing treatments for glaucoma, and should also benefit the Company's efforts to discover and develop treatments for chronic pain, stroke, traumatic brain injury, and Parkinson's disease" Extension of Allergan collaboration came on Dec 6th, 1999. Takes them to Nov 2000 with 1.25m research support plus potential milestones up to 16m and royalties. The Jan 4th, 2000 PR speaks of 5161 with Algos and Endo, maybe this has something to do with what Yukon said, but matters not, cnsi seems cheap and well managed and that is good enough for me. And look ma--no trades!